Dennis, J. M., Young, K. G., McGovern, A. P., Mateen, B. A., Vollmer, S. J., Simpson, M. D., … Shields, B. M. (2022). Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study. Lancet Digit Health, 4, e873-e883. http://doi.org/10.1016/s2589-7500(22)00174-1
R. Holman
First name
R.
Middle name
R.
Last name
Holman
Cook, M. N., Girman, C. J., Stein, P. P., Alexander, C. M., & Holman, R. R. (2005). Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care.
Farmer, A. J., Rodgers, L. R., Lonergan, M. ., Shields, B. ., Weedon, M. N., Donnelly, L. ., … Hattersley, A. T. (2016). Adherence to Oral Glucose-Lowering Therapies and Associations With 1-Year HbA1c: A Retrospective Cohort Analysis in a Large Primary Care Database. Diabetes Care. http://doi.org/10.2337/dc15-1194
Dennis, J. M., Henley, W. E., Weedon, M. N., Lonergan, M. ., Rodgers, L. R., Jones, A. G., … Hattersley, A. T. (2018). Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. Diabetes Care. http://doi.org/10.2337/dc18-0344
Dennis, J. M., Shields, B. M., Hill, A. V., Knight, B. A., McDonald, T. J., Rodgers, L. R., … Jones, A. G. (2018). Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. Diabetes Care. http://doi.org/10.2337/dc17-1827
Dennis, J. M., Henley, W. E., McGovern, A. P., Farmer, A. J., Sattar, N. ., Holman, R. R., … Jones, A. G. (2019). Time trends in prescribing of type 2 diabetes drugs, glycemic response and risk factors: a retrospective analysis of primary care data, 2010-2017. Diabetes Obes Metab. http://doi.org/10.1111/dom.13687
McGovern, A. P., Hogg, M. ., Shields, B. M., Sattar, N. A., Holman, R. R., Pearson, E. R., … Dennis, J. M. (2020). Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2020-001238